Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aucubin SCHEMBL381032 | 1.00 | L3MBTL1 (1.00) | L3MBTL1HSP90AA1XDHELANEPTPN1 | |
| Aucubin SCHEMBL22680275 | 1.00 | L3MBTL1 (1.00) | L3MBTL1HSP90AA1XDHELANEPTPN1 | |
| SCHEMBL30558037 | 0.86 | L3MBTL1 (0.75) | L3MBTL1HSP90AA1XDHMEN1KMT2A | |
| SCHEMBL421128 | 0.83 | L3MBTL1 (0.70) | L3MBTL1HSP90AA1ELANEPTPN1 | |
| Agnuside SCHEMBL24174405 | 0.81 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDH | |
| Agnuside SCHEMBL382107 | 0.81 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDH | |
| SCHEMBL7153129 | 0.81 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDHPTPN1 | |
| Agnuside SCHEMBL13208121 | 0.81 | L3MBTL1 (0.67) | L3MBTL1HSP90AA1XDH | |
| SCHEMBL2989887 | 0.78 | L3MBTL1 (0.64) | L3MBTL1HSP90AA1PTPN1 | |
| SCHEMBL13461206 | 0.78 | L3MBTL1 (0.64) | L3MBTL1ELANEPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166970-B2 | Composition for preventing or treating neurological disorder comprising aucubin | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20200360410-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDER COMPRISING AUCUBIN | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360410-A1 | COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDER COMPRISING AUCUBIN | SLC6A11, SLC6A1, SLC6A13 | L3MBTL1 3113/4885HSP90AA1 2064/4885XDH 717/4885 |
| US-11166970-B2 | Composition for preventing or treating neurological disorder comprising aucubin | SLC6A11, SLC6A1, SLC6A13 | L3MBTL1 3113/4885HSP90AA1 2064/4885XDH 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.